May 15, 2022
Article
In their paper, the researchers detail the first, to their knowledge, case of a potential gain of function phenotype for IL-33 in a human.
May 15, 2022
Article
According to recent findings, metabolizing disulfiram into diethyldithiocarbamate-copper complex creates a proteasome inhibitor-like treatment that enables the efficient killing of treatment-resistant multiple myeloma (MM) cells.
May 14, 2022
Article
The group noted that this transformation should affect changes at every level, including at the individual level during patient visits, at the organization level in how clinical encounters are organized, and at the national level in both policies and guidelines for type 1 diabetes (T1D).
May 14, 2022
Article
Among their sample cohort of 49 patients, the researchers found that scores on the Montreal Cognitive Assessment correlated with measures of both literacy and health literacy.
May 13, 2022
Article
The new findings come from a 15-year study examining the natural course of C-peptide in children and adolescents with type 1 diabetes (T1D).
May 12, 2022
Article
Hidradenitis suppurativa (HS) was associated with a variety of comorbid conditions, from psoriasis to hypertension.
May 10, 2022
Article
The study of constructed αROR1‐CAR T cells showed an increase of PD-L1 expression when exposed to elevated pressure, driving resistance to CAR T cell-mediated cytotoxicity. However, the findings also suggest that adding PD-1/PD-L1 inhibitors to CAR T-cell therapy could help address this.
May 08, 2022
Article
The findings, say the researchers, provide a basis for future exploration of the activity of energy metabolism pathways in clonal plasma cells of patients newly diagnosed with the disease.
May 07, 2022
Article
According to the researchers of this new study, the biomarker may have potential for use with clinical scores in treatment decisions or in clinical trials that focus on hidradenitis suppurativa (HS).
May 07, 2022
Article
The researchers highlighted a need for the detection of more relevant markers and guidance on how to treat adverse events (AEs), the types and severity of which vary based on disease type.